Handel nachbörslich: 10.29 0.13 +1.28%

Cybin Inc (CYBN)

Überblick Nachrichten Preisverlauf Forum Prognose

Cybin Inc Aktie (CYBN) Neueste Nachrichten

Cybin Inc (CYBN)

Cybin Inc Aktie (CYBN) Neueste Nachrichten

HC Wainwright Has Bearish Estimate for Cybin Q3 Earnings - MarketBeat

Cybin Stock In Focus On MDD Treatment's 'Breakthrough’ Efficacy: Retail Turns Extremely Bullish - MSN

Cybin’s Breakthrough: Psychedelic Depression Drug CYB003 Sustains 12-Month Symptom Remission in Major Depressive Disorder - geneonline

H.C. Wainwright reiterates Buy on Cybin stock, sees strong potential for CYB003 in MDD - Investing.com

Breakthrough Therapy Shows Promising Long-Term Results for Depression - Streetwise Reports

Cybin (NYSE:CYBN) Receives Buy Rating from HC Wainwright - MarketBeat

Cybin Reports Positive Phase 2 Data for CYB003 - The Dales Report

Cybin’s CYB003 Shows Promising Results for Depression - TipRanks

Cybin reports sustained depression treatment effects - Investing.com

Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder - Business Wire

Cybin posts second-quarter loss widens as clinical trials advance - Green Market Report

Canaccord Genuity Group Lowers Cybin (NYSE:CYBN) Price Target to $86.00 - MarketBeat

Cybin to Present 12-Month Phase 2 Data for CYB003 in Major Depressive Disorder on November 18, 2024 - BioSpace

Cybin to Present Promising CYB003 Study Results - TipRanks

Cybin to Showcase Promising Depression Treatment Progress - TipRanks

Cybin Phase 3 Layout - Green Market Report

CYBNCybin Inc. Latest Stock News & Market Updates - StockTitan

Cybin Inc (CYBN-NE) QuotePress Release - The Globe and Mail

Cybin launches new program phase to treat Major Depressive Disorder | 2024-11-13 | Investing News - Stockhouse Publishing

Cybin’s Phase 3 Trials and Financial Update - TipRanks

Can Canada’s psychedelic drug developers shake off the sector’s bad trip? - The Globe and Mail

Cybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results - StreetInsider.com

Cybin Inc. Begins Phase 3 Trials, Betting Big On CYB003 To Treat Depression - Benzinga

Cybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results – Company AnnouncementFT.com - Financial Times

What might RFK Jr’s psychedelic strategy look like? - Proactive Investors USA

Cybin Faces Key Data Readouts For Major Depressive Disorder, Generalized Anxiety Disorder - RTTNews

Learn to Evaluate (CYBN) using the Charts - Stock Traders Daily

Cybin Inc. (NYSE:CYBN) Stake Lowered by Rosalind Advisors Inc. - MarketBeat

Cybin (OTCMKTS:CYBN) Trading Up 0.2%Here's What Happened - MarketBeat

Cybin, Inc.Why Compass Pathways Is No Compass for Cybin's Progression Prospects - Smartkarma

PDS Planning Inc Sells 885,540 Shares of Cybin Inc. (NYSE:CYBN) - MarketBeat

Cybin Inc: Another High-Risk Psychedelics Play (NYSE:CYBN) - Seeking Alpha

Cybin to Participate at the 2024 Milken Institute Future of Health Summit - BioSpace

Cybin to Highlight Innovations at Health Summit - TipRanks

TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail

(CYBN) Pivots Trading Plans and Risk Controls - Stock Traders Daily

EXCLUSIVE: Neuropsychiatry-Focused Cybin Secures First US Composition of Matter Patent For Preclinical CYB005 Phenethylamines Program - MSN

Cybin secures patent for CNS disorder treatment candidates - Investing.com

Cybin announces grant of patent in support of CYB005 phenethylamines program - TipRanks

Cybin Announces Grant of First U.S. Composition of Matter Patent in Support of its CYB005 Phenethylamines Program - Business Wire

$DRUG 5,900% Weekly Surge Turns Attention. Cybin ($CYBN) Rallying 23% This Week In Anticipation For Major Milestones - FinanceFeeds

Sanctuary Advisors LLC Makes New Investment in Cybin Inc. (NYSE:CYBN) - MarketBeat

Cybin (NYSE:CYBN) Trading Down 7.4%What's Next? - MarketBeat

Cybin (NYSE:CYBN) Stock Price Up 9.7%What's Next? - MarketBeat

Undercovered Dozen: Endava, Cross Country Healthcare, Cybin, Equinor + - Seeking Alpha

(CYBN) Trading Signals - Stock Traders Daily

Cybin: Top Value Psychedelic Stock (NYSE:CYBN) - Seeking Alpha

Cybin (NYSE:CYBN) Shares Gap DownWhat's Next? - MarketBeat

Cybin (OTCMKTS:CYBN) Trading 1.5% HigherHere's What Happened - MarketBeat

Cybin (NYSE:CYBN) Shares Up 5.4%Still a Buy? - MarketBeat

(CYBN) Investment Analysis and Advice - Stock Traders Daily

PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) CEO to Participate in Upcoming Water Tower Research Fireside Chat - MSN

Ähnlich wie CYBN